S&P DJI Announces March 2024 Quarterly Rebalance
Filed with ASX · · 8 pages · English
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- Half Yearly Report and Accounts
- Prospectus - 2024 Non-Renounceable Rights Issue
- Rights Issue Offer to Raise Up To $6.6 million
- Quarterly Activities Report and Appendix 4C - Dec23
- Strategy & Market Update
Later from Rhythm Biosciences
- Internationally Renowned Clinical Advisory Board Established
- Close of Rights Issue
- Rhythm Maintains ISO Certification
- Dr David Atkins appointed Chief Executive Officer of Rhythm
- Mar24 Quarterly Activities Report and Appendix 4C
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences